Phase II study of chemoradiotherapy with 5-FU plus cisplatin followed by S-1 for clinical stage IA esophageal cancer (definitive chemoradiotherapy) - Phase II study of chemoradiotherapy with 5-FU plus cisplatin followed by S-1 for clinical stage IA esophageal cancer

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine0 个研究点目标入组 30 人开始时间: 2014年12月15日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Previous treatment with pyrimidine fluoride drug or platinum within 5 years 2) With active diseases (interstitial pneumonia, fibroid lung, intestinal obstruction, uncontrollable diabetes millutus or hypertentsion, history of myocardial infarction within 6 months, or unstable angina pectoris, liver cirrhosis, renal failure) 3) Simultaneous or metachronous cancers, with the exception of tumor curable with therapy before diagnosis of esophageal cancer 4) History of severe allergic reactions to pyrimidine fluoride drug or platinum 5) Active infection 6) Positive HBs antigen 7) Previous radiotherapy to chest 8) With severe diarrhea 9) Psychosis 10) Pregnant or lactating women, women of childbearing potential or women who like to have children in future 11) Patients requiring the administration of flucytosine, phenytoin or warfarin potassium 12) Any patients judged by the investigator to be unfit to participate in the study

发起方

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine